Update on Erythropoiesis-Stimulating Agents Administered to Neonates for Neuroprotection
- PMID: 31676737
- DOI: 10.1542/neo.20-11-e622
Update on Erythropoiesis-Stimulating Agents Administered to Neonates for Neuroprotection
Abstract
Erythropoiesis-stimulating agents (ESAs) such as erythropoietin and darbepoetin have been studied as red blood cell growth factors in preterm and term infants for more than 30 years. Recently, studies have focused on the potential neuroprotective effects of ESAs. In this review, we summarize preclinical animal models and recent clinical trials that provide evidence for ESAs as potential treatments to improve neurodevelopmental outcomes in preterm and term infants.
Copyright © 2019 by the American Academy of Pediatrics.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
